Overall, these studies show that the simultaneous targeting of APE1 redox and STAT3 signaling synergize to markedly impair the survival of human pancreatic cancer cells, even at sub-optimal doses of the individual agents. Here, APEX1 is linked to pancreatic neoplasm.